// App-Quantinova.ai

2506 : A first-in-human (FIH) phase I study of SAR125844, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results.

Researchers

Presenter

  • Eric Angevin

Principal Investigators

  • Gianluca Spitaleri

  • Marzia Harnois

  • Florent Mazuir

  • Sylvie Assadourian

  • Filippo De Marinis

Medical Centers

  • Sanofi R&D, Vitry-Sur-Seine, France

  • and an Institute of Oncology, Milano, ItalyDrug Development Department (DITEP), Gustave Roussy Institute, Villejuif, FranceD, Chilly-Mazarin, France

  • Istituto Europeo di Oncologia, Milano, Italy

  • European Institute of Oncology, Milan, Italy

  • Institut Gustave-Roussy, Villejuif, France

  • Drug Development Department, Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France

Locations

  • France

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • SAR125844

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01391533

Sponsors

  • Sanofi

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved